Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Johannes Irsch"'
Autor:
Maja Weisser, Nina Khanna, Anemone Hedstueck, Sarah Tschudin Sutter, Sandra Roesch, Gregor Stehle, Mihaela Sava, Nikolaus Deigendesch, Manuel Battegay, Laura Infanti, Andreas Holbro, Stefano Bassetti, Hans Pargger, Hans H. Hirsch, Karoline Leuzinger, Laurent Kaiser, Diem‐Lan Vu, Katharina Baur, Nadine Massaro, Michael Paul Busch, Graham Simmons, Mars Stone, Philip L. Felgner, Rafael R. de Assis, Saahir Khan, Cheng‐ting Tsai, Peter V. Robinson, David Seftel, Johannes Irsch, Anil Bagri, Andreas S. Buser, Laurence Corash
Publikováno v:
Transfusion. 62(10)
Efficacy of donated COVID-19 convalescent plasma (dCCP) is uncertain and may depend on antibody titers, neutralizing capacity, timing of administration, and patient characteristics.In a single-center hypothesis-generating prospective case-control stu
Publikováno v:
Transfusion. 62(8)
Autor:
Ottar Rolfsson, Johannes Irsch, Olafur E. Sigurjonsson, Niels Arni Arnason, Björn Hardarsson, Sveinn Vidar Gudmundsson, Ragna Landrö, Freyr Johannson
Publikováno v:
Transfusion. 59:3727-3735
Background To reduce the risk of transfusion transmission infection, nucleic acid targeted methods have been developed to inactivate pathogens in PCs. miRNAs have been shown to play an important role in platelet function, and changes in the abundance
Autor:
Johannes Irsch, David Tappe, Daniel Bolliger, Andreas Holbro, Laurence Corash, Jin-Sying Lin, Jakob Passweg, Richard J. Benjamin, Ramona Merki, Laura Infanti, Alexandra Plattner, Andreas Buser, Dimitrios A. Tsakiris
Publikováno v:
Transfusion
BACKGROUND Universal pathogen inactivation of platelet concentrates (PCs) using amotosalen/ultraviolet A with 7-day storage was implemented in Switzerland in 2011. Routine-use data were analyzed at the University Hospital Basel, Switzerland. STUDY DE
Autor:
Jean-Marc Payrat, Yvette A. Girard, Johannes Irsch, Marion C. Lanteri, Andrew Laughhunn, Marcus Picard-Maureau, Adonis Stassinopoulos, Felicia Santa‐Maria, Peter Bringmann
Publikováno v:
Transfusion
Background The INTERCEPT Blood System pathogen reduction technology (PRT), which uses amotosalen and ultraviolet A light treatment (amotosalen/UV-PRT), inactivates pathogens in plasma and platelet components (PCs). This review summarizes data describ
Autor:
Lily Lin, Johannes Irsch
Publikováno v:
Transfusion Medicine and Hemotherapy
BACKGROUND: The transmission of pathogens via blood transfusion is still a major threat. Expert conferences established the need for a pro-active approach and concluded that the introduction of a pathogen inactivation/reduction technology requires a
Publikováno v:
Allergy. 53:233-240
By rush bee-venom immunotherapy, subjects reacting allergically to the venom can be effectively anergized, although the mechanism of action is not known. Here we analyzed the systemic effects of rush desensitization on the T cells of allergic patient
Publikováno v:
AIDS. 15:810-812
Autor:
Thomas Müller, Lily Lin, Axel Seltsam, Wilhelm G. Struff, Nina Mufti, Reinhard Henschler, Peter Bugert, Susanne Marschner, K. Janetzko, Stefan Reichenberg, Erhard Seifried, Peter Hellstern, Johannes Irsch, Jerard Seghatchian, Bjarte G. Solheim, Raymond P. Goodrich
Publikováno v:
Transfusion Medicine and Hemotherapy. 38:73-74
Autor:
Nicolas Hunzelmann, Stefan Miltenyi, Mario Assenmacher, Johannes Irsch, Heike Leyendeckers, Andreas Radbruch, Jürgen Schmitz, Andrea Löhndorf, Michael D. Spangfort, Marcus Odendahl
Publikováno v:
European journal of immunology. 29(4)
Recent studies in mice have indicated that the long-lasting specific antibody responses seen after vaccination are probably due to the existence of long-lived plasma cells. Therefore, because the maintenance of humoral immunity does not necessarily r